N-Acetyl-5-hydroxytryptamine (NAS, N-Acetylserotonin, Normelatonin, O-Demethylmelatonin), a precursor of melatonin, is a potent and selective agonist of TrkB receptor.
research use only
Cat.No.S2985
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease Tyrosinase DPP HIV Protease |
|---|---|
| Other Trk receptor Inhibitors | ANA-12 GW441756 7,8-Dihydroxyflavone GNF-5837 Selitrectinib (LOXO-195) LM22B-10 Altiratinib LM22A-4 CH7057288 PF-06273340 |
|
In vitro |
DMSO
: 43 mg/mL
(197.02 mM)
Ethanol : 43 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 218.25 | Formula | C12H14N2O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1210-83-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | NAS, N-Acetylserotonin, Normelatonin, O-Demethylmelatonin | Smiles | CC(=O)NCCC1=C[NH]C2=C1C=C(O)C=C2 | ||
| Targets/IC50/Ki |
TrkB receptor
|
References |
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06154590 | Not yet recruiting | Metastatic Breast Cancer|Tumor|Muscle Neoplasms|Chronic Pain |
DR. DIANE CHISESI NFS. MD. PHD.|IRB|Paradyne Networks A Foundation |
July 2024 | -- |
| NCT06322628 | Not yet recruiting | Nash |
Visirna Therapeutics HK Limited |
April 2024 | Phase 2 |
| NCT06318169 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis |
89bio Inc. |
March 13 2024 | Phase 3 |
| NCT05979389 | Recruiting | NAFLD|PCOS |
University of California San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
February 14 2024 | Phase 1 |
| NCT05118360 | Withdrawn | Nonalcoholic Steatohepatitis (NASH) |
Gannex Pharma Co. Ltd. |
December 1 2023 | Phase 2 |
| NCT06215716 | Recruiting | NASH With Fibrosis|MASH With Fibrosis |
Akero Therapeutics Inc |
December 1 2023 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.